Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17443912 | 0.88 | USP2 (0.37) | CYP4F2CYP4A11 | |
| SCHEMBL5007026 | 0.85 | DGAT1 (0.35) | CYP4F2CYP4A11DGAT1 | |
| SCHEMBL5007117 | 0.85 | DGAT1 (0.35) | CYP4F2CYP4A11DGAT1 | |
| SCHEMBL517398 | 0.83 | CYP4F2 (0.40) | CYP4F2CYP4A11DGAT1 | |
| SCHEMBL517246 | 0.80 | CYP4F2 (0.42) | CYP4F2CYP4A11DGAT1TDP1 | |
| SCHEMBL13523795 | 0.79 | — | — | |
| SCHEMBL518170 | 0.79 | CYP4F2 (0.38) | CYP4F2CYP4A11DGAT1 | |
| SCHEMBL10004678 | 0.78 | CYP4F2 (0.48) | CYP4F2CYP4A11DGAT1TDP1 | |
| SCHEMBL17033330 | 0.78 | CYP4F2 (0.46) | CYP4F2CYP4A11 | |
| SCHEMBL517362 | 0.76 | CYP4F2 (0.39) | CYP4F2CYP4A11DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230083012-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. (CN) | 2023-03-16 | — | — | US | disclosed |
| CN-114173787-A | Dihydropyrimidine derivatives and their use in the treatment of HBV infection or HBV-induced diseases | 杨森科学爱尔兰无限公司 | 2022-03-11 | — | — | CN | disclosed |
| US-11130750-B2 | Calcium channel inhibitors | CAVION, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-11130750-B2 | Calcium channel inhibitors | CAVION, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-20200385367-A1 | CALCIUM CHANNEL INHIBITORS | CAVION, INC. | 2020-12-10 | — | — | US | disclosed |
| US-20200385367-A1 | CALCIUM CHANNEL INHIBITORS | CAVION, INC. | 2020-12-10 | — | — | US | disclosed |
| CN-110545806-A | calcium channel inhibitors | CAVION INC | 2019-12-06 | — | — | CN | disclosed |
| WO-2018152317-A1 | CALCIUM CHANNEL INHIBITORS | CAVION, INC. (US) | 2018-08-23 | — | — | WO | disclosed |
| CN-102762541-B | Diaza derivatives as modulators of chemokine receptors | HOFFMAN-LA ROCHE LTD. (CH) | 2016-03-16 | — | — | CN | disclosed |
| EP-2491022-B1 | DIAZEPAN DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | HOFFMANN LA ROCHE (CH) | 2014-12-31 | — | — | EP | disclosed |
| EP-1688412-A2 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | Aventis Pharmaceuticals, Inc. (US) | 2006-08-09 | — | — | EP | disclosed |
| EP-1632483-A1 | HETEROCYCLIC SUBSTITUTED CARBONYL DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | Aventis Pharmaceuticals Inc. (US) | 2006-03-08 | — | — | EP | disclosed |
| EP-1362039-B1 | HETEROCYCLIC SUBSTITUTED CARBONYL DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | AVENTIS PHARMA INC (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20050107389-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-19 | — | — | US | disclosed |
| US-20040220173-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor | AVENTIS PHARMACEUTICAL INC. (US) | 2004-11-04 | — | — | US | disclosed |
| US-20040030137-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-02-12 | — | — | US | disclosed |
| EP-1361875-A2 | NOVEL HETEROCYCLIC AMIDE DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | Aventis Pharmaceuticals Inc. (US) | 2003-11-19 | — | — | EP | disclosed |
| EP-1362039-A1 | HETEROCYCLIC SUBSTITUTED CARBONYL DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | Aventis Pharmaceuticals, Inc. (US) | 2003-11-19 | — | — | EP | disclosed |
| WO-2002066469-A2 | NOVEL HETEROCYCLIC AMIDE DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | AVENTIS PHARMACEUTICALS INC. (US) | 2002-08-29 | — | — | WO | disclosed |
| WO-2002066446-A1 | HETEROCYCLIC SUBSTITUTED CARBONYL DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | AVENTIS PHARMACEUTICALS INC. (US) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11130750-B2 | Calcium channel inhibitors | CACNA1F, ORAI1, CACNA1E | CYP4F2 2875/4885CYP4A11 4670/4885DGAT1 3824/4885 |
| US-20040030137-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | DRD3, DRD2, DRD1 | CYP4F2 1781/4885CYP4A11 2653/4885DGAT1 1574/4885 |
| US-20200385367-A1 | CALCIUM CHANNEL INHIBITORS | CACNA1F, ORAI1, CACNA1E | CYP4F2 2875/4885CYP4A11 4670/4885DGAT1 3824/4885 |
| US-20050107389-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | DRD3, DRD2, DRD1 | CYP4F2 1765/4885CYP4A11 2514/4885DGAT1 1491/4885 |
| US-20040220173-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor | DRD3, DRD2, DRD1 | CYP4F2 1254/4885CYP4A11 1708/4885DGAT1 2214/4885 |
| US-20230083012-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | DPYD, HAVCR2, TYMP | CYP4F2 420/4885CYP4A11 446/4885DGAT1 3188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.